This 15-minute accredited CME publication reviews the mechanisms of action and clinical data of 2 new approved therapies for active secondary progressive multiple sclerosis (SPMS). Highlights include a discussion on SPMS pathophysiology and how newer therapies may address both the inflammatory and degenerative aspects of the disease. In addition, this activity features a short video that provides expert commentary from Mark Skeen, MD, on the current management landscape for patients with SPMS.
Mark B. Skeen, MD, FACP, FAAN
Associate Professor of Neurology
Head, Division of Multiple Sclerosis and Neuroimmunology